Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756378 | 0.88 | CA12 (0.58) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL11100708 | 0.86 | CA12 (0.63) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL27592314 | 0.85 | ALDH1A1 (0.66) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL28347887 | 0.84 | CA12 (0.61) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL6406957 | 0.84 | CA12 (0.61) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL1951310 | 0.83 | CA12 (0.56) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL27346972 | 0.83 | CA12 (0.59) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL15720647 | 0.82 | CA12 (0.63) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL1949474 | 0.82 | CA12 (0.55) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL15317893 | 0.82 | CA12 (0.55) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107430355-B | Coating liquid for coating resist pattern and pattern forming method | 日产化学工业株式会社 | 2023-07-14 | — | — | CN | claimed |
| CN-118978566-A | Method for modifying polypeptide methionine locus thioimine and application thereof | 兰州大学 | 2024-11-19 | — | — | CN | disclosed |
| WO-2023212650-A1 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-107430355-B | Coating liquid for coating resist pattern and pattern forming method | 日产化学工业株式会社 | 2023-07-14 | — | — | CN | disclosed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| CN-103402997-B | Diaminopyrimidine derivatives and process for preparing same | Liu Hanyangxing (KR) | 2015-08-26 | — | — | CN | disclosed |
| CN-103097375-B | Cyclohexyl-azetidine the antagonist of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-08-12 | — | — | CN | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| CN-103097375-A | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV | 2013-05-08 | — | — | CN | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
| EP-1656138-A4 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1656138-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2002053616-A1 | NEW LINEAR BLOCK POLYMER | ARTIMPLANT AB (SE) | 2002-07-11 | — | — | WO | disclosed |
| US-5831091-A | Process for preparing acetoxyazetidinone derivative and intermediate thereof | TANABE SEIYAKU CO., LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| EP-0774463-A1 | Process for preparing acetoxyazetidinone derivative and intermediates thereof | TANABE SEIYAKU CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| CN-1017337-B | PROCESS FOR PREPARING PHOSPHINIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1992-07-08 | — | — | CN | disclosed |
| CN-87101164-A | PHOSPHINIC ACID DERIVATIVES | — | 1988-06-29 | — | — | CN | disclosed |
| US-4160077-A | Process of crosslinking unsaturated hydrocarbon polymers employing novel carbamates | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | ALDH1A1 198/4885CA12 1963/4885CA1 1379/4885 |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | ALDH1A1 198/4885CA12 1963/4885CA1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.